证券代码：600833 证券简称：第一医药 公告编号：临 2025-052 上海第一医药股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 12 月 5 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于召开 2025 年第三季度业绩说明会的公告》（公告编号：临 2025-051）。 公司党委书记、董事长张海波先生，党委副书记、副董事长、总经理姚军先 生，独立董事汪丰先生、唐松莲女士、陈少雄先生以及董事会秘书、财务总监孙 峥先生出席了本次说明会，就公司 2025 年第三季度的经营成果及财务指标等情 况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者关注的问题 进行了回复。 二、投资者提出的问题及公司回复情况 公司通过上海证券交易所上证路演中心就投资者提出的问题进行了回复，具 体如下： 1.公司有化妆护肤产品吗？ 答：尊敬的投资者，您好。目前公司在营店型中，有消费人群定位于"年轻 妈妈"的健康小站，提供包括美妆日化、营养 ...

Core Viewpoint - The company, First Pharmaceutical, is focusing on business expansion and brand promotion, with a positive operational trend in its stores as of June 30, 2025, expecting to have 208 stores, including 42 franchise stores [1] Group 1 - As of June 30, 2025, the company plans to operate 208 stores, which includes 42 franchise stores [1] - The company has been continuously focusing on business expansion and brand promotion since the opening of its first "pet-friendly pharmacy" [1] - The trend of consumers bringing pets into stores for consultations and purchases has become a regular occurrence [1]

Core Viewpoint - Shanghai First Pharmaceutical Co., Ltd. is set to hold a Q3 2025 earnings presentation on December 12, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Earnings Presentation Details - The earnings presentation will take place on December 12, 2025, from 15:00 to 16:00 [4][5]. - The presentation will be conducted in an interactive online format via the Shanghai Stock Exchange Roadshow Center [3][5]. - Investors can submit questions from December 5, 2025, to December 11, 2025, before 16:00, either through the Roadshow Center or via the company's email [2][6]. Group 2: Company Representatives - Key representatives at the earnings presentation will include Chairman Zhang Haibo, Vice Chairman and General Manager Yao Jun, and Board Secretary and CFO Sun Zheng [4]. - Independent directors Wang Feng, Tang Songlian, and Chen Shaoxiong will also be present [4]. Group 3: Contact Information - Investors can contact the company's board office for inquiries at phone number 021-64337282 or via email at shcred@online.sh.cn [6]. - After the presentation, details and key content will be available on the Shanghai Stock Exchange Roadshow Center [6].

证券代码：600833 证券简称：第一医药 公告编号：临 2025-051 上海第一医药股份有限公司 投资者可于 2025 年 12 月 05 日（星期五）至 12 月 11 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shcred@online.sh.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海第一医药股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 12 日（星期五） 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2025 年第三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容 ...

Core Viewpoint - The transformation of traditional pharmacies into comprehensive health service centers is driven by AI technology and strategic initiatives from First Pharmaceutical, aiming to adapt to the evolving pharmaceutical retail landscape and meet consumer demands in the health sector [1][2][3]. Group 1: Industry Challenges - The pharmaceutical distribution industry is facing unprecedented challenges, including changes in policy environment, sales models, professional capabilities, and expansion logic [2][3]. - The implementation of drug traceability codes, increased regulation, and continuous price reductions are fundamentally altering the profitability of pharmacies [3]. - The rise of O2O instant retail has fostered a consumer habit of purchasing medications without visiting physical stores, leading to declining foot traffic in traditional pharmacies [3]. Group 2: Company Performance - First Pharmaceutical's revenue increased from 1.398 billion to 1.915 billion from 2021 to 2024, while total profit rose from 65 million to 216 million [3]. - The number of stores doubled from 115 to 206, reflecting the company's proactive strategies and innovations [3]. Group 3: Strategic Focus - The company is aligning its strategic planning with national initiatives, particularly focusing on the silver economy and integrating traditional Chinese medicine into its service offerings [4][5]. - First Pharmaceutical aims to create a "professional integrated elderly care service platform" by enhancing community store services and collaborating with third parties for home care and health monitoring [5]. Group 4: Technological Integration - The company is exploring AI-assisted diagnostic technologies to address the scarcity of experienced traditional Chinese medicine practitioners and to attract younger consumers [6]. - Plans include the introduction of an "AI health management smart engine" combined with wearable devices for personalized health management [6]. Group 5: Capital Market Strategy - First Pharmaceutical is leveraging capital market opportunities to drive growth, focusing on value management and potential mergers and acquisitions [7]. - The company is enhancing its internal mechanisms and performance assessment systems to boost employee motivation and align interests with long-term corporate goals [7]. Group 6: Future Vision - The company envisions transforming pharmacies into "community health service centers" that integrate various health services, including traditional medicine and chronic disease management [8]. - First Pharmaceutical aims to become a leading pharmaceutical and health service provider in the Yangtze River Delta region by refining its operations and strengthening its support systems [8].

Group 1 - Several companies, including Shuyupingmin, Huaren Health, and Kaikai Industry, experienced a decline of over 6% [1] - Other companies such as Yaoyigou, Renmintongtai, Yingtigroup, Diyi Medical, and Yifeng Pharmacy also followed the downward trend [1]

Core Viewpoint - Shanghai First Pharmaceutical Co., Ltd. has approved a series of strategic initiatives aimed at enhancing operational efficiency, improving corporate governance, and increasing shareholder returns during its 11th Board of Directors' sixth meeting held on November 21, 2025 [2][3][8]. Group 1: Action Plan for 2025 - The company has developed a "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, focusing on optimizing operational efficiency and enhancing corporate governance to drive high-quality development and investment value [3][8]. - The company aims to enhance its core business, which includes retail and wholesale pharmaceutical services, and to provide comprehensive health services [8][9]. - In 2024, the company reported a revenue of 1.915 billion yuan, a year-on-year increase of 5.26%, and a net profit of 163 million yuan, up 82.65% from the previous year [9]. Group 2: Governance and Compliance - The company has established a governance structure that includes a clear division of responsibilities among the shareholders' meeting, board of directors, and management, ensuring effective coordination and accountability [9][10]. - The company has revised several internal regulations to align with regulatory changes and improve governance practices, including the transformation of the Strategic Committee into a Strategic and ESG Committee [10]. Group 3: Investor Relations and Disclosure - The company emphasizes the importance of high-quality information disclosure and investor relations management, ensuring compliance with relevant regulations and providing timely updates to investors [11][12]. - The company plans to enhance its communication channels with investors, ensuring transparency and responsiveness to investor concerns [11][12]. Group 4: Shareholder Returns - The company is committed to a sustainable and stable shareholder return mechanism, having distributed cash dividends amounting to 49.079 million yuan in 2024, which represents approximately 30.10% of the net profit attributable to shareholders [12]. - Future strategies will focus on balancing long-term development with immediate shareholder interests, ensuring continuity and stability in profit distribution policies [12]. Group 5: Management of Key Personnel - The company maintains close communication with key stakeholders, including controlling shareholders and senior management, to enhance compliance awareness and responsibility [13]. - In 2025, the company will continue to monitor regulatory changes and provide training to key personnel to ensure adherence to compliance standards [13].

Group 1 - The company announced the formulation of the "2025 Quality Improvement and Efficiency Enhancement Action Plan" [2] - The plan focuses on five key areas: enhancing core business operations, improving governance, increasing the quality of information disclosure, prioritizing investor returns, and strengthening management accountability [2]

Market Overview - On November 21, the Shanghai State-Owned Enterprise Reform sector fell by 2.97% compared to the previous trading day, with Tibet City Investment leading the decline [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Shanghai Mechanical and Electrical (600835) saw a closing price of 28.29, with an increase of 4.89% and a trading volume of 427,300 shares, amounting to a transaction value of 1.207 billion [1] - Tibet City Investment (600773) experienced a significant drop of 10.02%, closing at 12.93, with a trading volume of 473,100 shares [2] - Hydrogen Alkali Chemical (600618) and Data Port (603881) also faced declines of 9.53% and 7.83%, respectively [2] Capital Flow - The Shanghai State-Owned Enterprise Reform sector saw a net outflow of 2.59 billion yuan from institutional investors, while retail investors had a net inflow of 2.12 billion yuan [2] - The main capital flow data indicates that Shanghai Mechanical and Electrical had a net inflow of 1.20 billion yuan from institutional investors, while retail investors had a net outflow of 43.99 million yuan [3]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-050 上海第一医药股份有限公司 二、规范运作管理，提升公司治理水平 公司严格按照《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规、 规范性文件和《公司章程》规定，构建了以股东会、董事会及专门委员会和管理层为核 心主体的治理结构，形成了权力机构、决策机构、监督机构和管理层之间分工明确、权 责清晰、协调运作、相互制约的治理机制，构建了紧密衔接、高效协同的治理与管理架 构。 2024 年以来，公司根据监管政策变化及经营需求，修订《公司章程》《独立董事工 作细则》等多项内部制度，创新独立董事选任机制，荣获上海辖区独立董事制度改革"优 秀实践"案例，进一步夯实治理基础。同时，公司将董事会战略委员会变更为战略与 ESG 委员会，并完成监事会撤销流程，相应职责由董事会审计委员会承接，有效提升公司可 持续健康发展和管理运作水平。 未来，公司将持续提升治理水平，紧密关注证监会、交易所最新监管政策，及时修 订内部管理制度以适配监管要求与公司发展阶段；组建覆盖医保合规、药品追溯等领域 的合规管理标准化体系并定期开展风险排查；明确独立董事履职定位与保障 ...